NeOnc Technologies Holdings, Inc. (NTHI) company profile
Close on Nov 18, 2026Market cap $107.90MP/E –Yield –
About NeOnc Technologies
Pharmaceutical Preparations, SIC 2834
NeOnc Technologies is a clinical-stage biopharmaceutical company focused on developing therapies and novel delivery modalities for intracranial malignancies, including primary brain tumors such as glioblastoma and meningioma, as well as secondary brain metastases. The company's pipeline centers on two investigational candidates: NEO100, a purified perillyl alcohol administered intranasally to bypass the blood-brain barrier, and NEO212, an oral and intranasal conjugate of temozolomide and perillyl alcohol. NeOnc currently conducts human clinical trials across targeted patient populations lacking effective alternatives, while also exploring delivery applications for neurodegenerative conditions.
The company operates without commercial products, revenue-generating customer accounts, or internal sales infrastructure, relying on clinical trials and regulatory reviews to advance its pipeline. Corporate operations and sponsored clinical research are based out of Los Angeles, California. In addition to multi-institutional clinical trial sites across the United States, NeOnc engages in collaborative research partnerships, including initiatives extending clinical development into the Gulf Cooperation Council region.
Summary of the business section of NeOnc Technologies's latest annual report, written by StockData.
Company profile
Company
- Legal name
- NeOnc Technologies Holdings, Inc.
- Founded
- 2008
- Headquarters
- Calabasas, CA
- Address
- 23975 Park Sorrento, Suite 205 91302
- Phone
- (310) 663-7831
- Website
- neonc.com
- Employees
- 5, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Marcum llp, Philadelphia, PA
Stock & identifiers
- Ticker
- NTHI
- Exchange
- Nasdaq
- IPO date
- Mar 25, 2025
- Shares outstanding
- 26M, Aug 10, 2026
- Public float
- $67.90M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1979414
- CUSIP
- 64051A101
- ISIN
- US64051A1016
- FIGI
- BBG01KPDB522
- Share class FIGI
- BBG01KPDB5X8
- EIN
- 92-1954864
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Amir F. Heshmatpour | CEO, President, Director | 7,873,140 |
| Thomas C. Chen | CMO, Director | 4,690,602 |
| Keithly Garnett | CFO | 281,410 |
| Yousha Neman-Ebrahim | Chief Clinical Officer | 134,760 |
| Suh, David Jr. | Chief Accounting Officer | 111,866 |
| Patrick Walters | COO | 876,373 |
| Ali Mohammad Ahmad Mohammad Alabedin | Director | – |
| Nasim Shomali | Director | 50,160 |
| Ming-Fu (Alan) Chiang | Director | 2,190,049 |
| Ishwar Kanwar Puri | Director | – |
| Jim Delshad | Director | 55,310 |
| Steven L. Giannotta | Director | 50,160 |
| Bader Almonawer | Director | 50,160 |
| Victoria Medvec | Director | 50,160 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Total | vs. prior year |
|---|---|---|---|
| Dr. Thomas C. Chen Chief Medical Officer | $212.00K | $212.00K | 0% |
| Keithly Garnett Chief Financial Officer | $179.00K | $179.00K | 0% |
| Josh Neman Chief Clinical Officer | $165.00K | $165.00K | -15% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Mar 25, 2025
- Securities offered
- 2,101,313
- Exchange
- Nasdaq
- First trading day
- Mar 26, 2025
- First-day close
- $12.11
- Lock-up ends (est.)
- Sep 22, 2025
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 22, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Aug 14, 2025 | Late filing | Notification of late filing |
| Apr 1, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Mar 25, 2025 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 24, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?